Why the study?
Vascular complications contribute to morbidity and mortality after TAVI, but studies on their incidence and predictors show conflicting results.
Does the modified sheath-to-femoral artery ratio (md-SFAR) better predict vascular complications compared to manufacturer's guidelines in patients undergoing transfemoral TAVI?
Does the modified sheath-to-femoral artery ratio (md-SFAR) better predict vascular complications compared to manufacturer's guidelines in patients undergoing transfemoral TAVI?
Answers are grounded in this paper and cite their sources.
The modified sheath-to-femoral artery ratio (md-SFAR) is an independent predictor of vascular complications in transfemoral TAVI and may improve patient selection compared to standard manufacturer guidelines.
OBJECTIVE: Vascular complications (VCs) contribute to increased morbidity and mortality in patients who have undergone transcatheter aortic valve implantation (TAVI); however, studies on their incidence and predictors show conflicting results. In this study, we sought to assess the incidence, impact, and predictors of VCs in transfemoral (TF) TAVI and also investigated the predictive role of manufacturer's size charts and a new predictor modified sheath-to-femoral artery ratio. METHODS: A total of 223 patients undergoing TF-TAVI were categorized into 2 groups. The patients were divided as eligible and ineligible according to the manufacturer's guidelines (MG), and the same patient cohort was dichotomized into eligible and ineligible on the basis of sheath-to-femoral artery ratio (SFAR) value of less than or greater than or equal to modified SFAR (md-SFAR). VCs (defined according to the Valve Academic Research Consortium II criteria) were retrospectively compared. RESULTS: According to the manufacturer's size charts, 65 patients were unsuitable; however, 35 patients were ineligible for TF-TAVI per the md-SFAR criteria. Although VCs occurred in 42 (18.8%) patients, 17 (27.7%) of those patients were classified as ineligible according to MG, whereas 14 (41.2%) were classified as ineligible in the md-SFAR group. In a multiple logistic regression analysis that included md-SFAR, MG, SFAR ≥1.05, peripheral artery disease, and minimum iliofemoral artery diameter, only md-SFAR was the independent predictor of VCs (odds ratio=3.71, 95% confidence interval=1.13-12.53, p=0.031). CONCLUSION: According to our results, md-SFAR might provide better patient selection to prevent VCs and improve outcomes in TF-TAVI procedures.
No takes yet. Share an insight, caveat, or question.
Çakal et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: